Company intelligence / Profile preview

广州市香雪新药开发有限公司

Guangzhou, Guangdong, China

Ownership: Private
Development stage: Other

Overview

Guangzhou Xiangxue New Drug Development Co., Ltd. is a wholly-owned R&D subsidiary of Guangzhou Xiangxue Pharmaceutical Co., Ltd. (SZSE: 300147). Established in 2010, the company is dedicated to the research, development, and commercialization of innovative therapeutics, with a primary focus on oncology. Its lead clinical candidate is KX02 (KX2-361), a lipophilic, brain-penetrating dual Src tyrosine kinase and tubulin polymerization inhibitor licensed from Kinex Pharmaceuticals (later Athenex) for development in Greater China and Singapore. KX02 is currently undergoing Phase 1 clinical trials in China for the treatment of malignant glioma and other solid tumors.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Pharma

Partnerships

Athenex

Beyond the preview

Go deeper on 广州市香雪新药开发有限公司.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 广州市香雪新药开发有限公司.

Explore the full profile